NEW YORK (GenomeWeb) – Illumina said this week that it is collaborating with pharmaceutical companies AstraZeneca, Janssen Biotech, and Sanofi to develop a next-generation sequencing-based panel to serve as a universal companion diagnostic.

The company told Clinical Sequencing News that it would leverage its US Food and Drug Administration-cleared MiSeqDx system to develop an oncology test kit that includes the NGS system, bioinformatics capabilities, and reagents necessary to target single nucleotide variants, indels, copy number variants, and gene fusions.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.